FBRX
Forte Biosciences Inc

2,991
Mkt Cap
$253.67M
Volume
67,543.00
52W High
$25.97
52W Low
$4.90
PE Ratio
-5.10
FBRX Fundamentals
Price
$22.65
Prev Close
$20.25
Open
$20.43
50D MA
$15.34
Beta
0.55
Avg. Volume
117,398.63
EPS (Annual)
-$12.17
P/B
3.37
Rev/Employee
$0.00
Loading...
Loading...
News
all
press releases
Stock Traders Purchase High Volume of Forte Biosciences Call Options (NASDAQ:FBRX)
Forte Biosciences, Inc. (NASDAQ:FBRX - Get Free Report) was the recipient of unusually large options trading activity on Wednesday. Traders acquired 30,205 call options on the company. This...
MarketBeat·1d ago
News Placeholder
More News
News Placeholder
Forte Biosciences Target of Unusually High Options Trading (NASDAQ:FBRX)
Forte Biosciences, Inc. (NASDAQ:FBRX - Get Free Report) was the recipient of unusually large options trading on Wednesday. Stock investors purchased 30,205 call options on the company. This is an...
MarketBeat·14d ago
News Placeholder
Forte Biosciences, Inc. (NASDAQ:FBRX) Receives Average Recommendation of "Moderate Buy" from Brokerages
Forte Biosciences, Inc. (NASDAQ:FBRX - Get Free Report) has been assigned a consensus rating of "Moderate Buy" from the five research firms that are presently covering the company, Marketbeat.com...
MarketBeat·16d ago
News Placeholder
Forte Biosciences (NASDAQ:FBRX) Posts Quarterly Earnings Results, Beats Expectations By $0.05 EPS
Forte Biosciences (NASDAQ:FBRX - Get Free Report) posted its earnings results on Friday. The company reported ($0.99) earnings per share for the quarter, topping the consensus estimate of ($1.04) by...
MarketBeat·26d ago
News Placeholder
Forte Biosciences (NASDAQ:FBRX) Downgraded to Sell Rating by Wall Street Zen
Wall Street Zen lowered shares of Forte Biosciences from a "hold" rating to a "sell" rating in a research note on Saturday...
MarketBeat·26d ago
News Placeholder
Forte Biosciences, Inc. Announces Third Quarter 2025 Results and Provides Update
Forte Biosciences, Inc. (www.fortebiorx.com) (NASDAQ: FBRX), a clinical-stage biopharmaceutical company focused on autoimmune and autoimmune-related diseases, today announced its third quarter 2025...
Business Wire·28d ago
News Placeholder
Forte Biosciences, Inc. to Present at Upcoming Healthcare Conferences
Forte Biosciences, Inc. (www.fortebiorx.com) (NASDAQ: FBRX), a clinical-stage biopharmaceutical company focused on autoimmune and autoimmune-related diseases, will be presenting at 3 upcoming...
Business Wire·1mo ago
News Placeholder
5 Stocks Retail Investors Are Most Bullish On At Mid-Day
Retailers went overboard about a couple of biotech stocks and a MedTech name, among others on Wednesday.
Stocktwits·1y ago
News Placeholder
Forte Biosciences Stock More Than Doubles On Oversubscribed $53M Private Placement: Retail Goes Wild
The funds will support clinical development of FB102, Forte’s proprietary anti-CD122 monoclonal antibody targeting autoimmune and autoimmune-related diseases.
Stocktwits·1y ago

Latest FBRX News

View

Advertisement|Remove ads.

Advertisement|Remove ads.